02 December 2021
Adalvo is pleased to announce that we have successfully submitted our EU DCP procedure for Nitrofurantoin ER 100mg Capsules, another differentiated product within our portfolio, that was developed based on the reference brand Macrobid.
Nitrofurantoin is an antimicrobial medication that is used in the treatment of acute uncomplicated urinary tract infections. Nitrofurantoin represents a niche market within the EU with total sales of $90mio in 2020 (IQVIA data, inclusive of all forms).
Adalvo has become the first and only known Company to successfully submit a DCP procedure for this product within the EU, allowing Adalvo and our partners to serve more patients across the globe.